Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

被引：32
|
作者：
Diefenbach, Catherine S. [1 ]
Hong, Fangxin [2 ]
David, Kevin A. [3 ]
Cohen, Jonathon [4 ]
Robertson, Michael [5 ]
Advani, Ranjana [6 ]
Palmisiano, Neil D. [7 ]
Ambinder, Richard F. [8 ]
Kahl, Brad S. [9 ]
Ansell, Stephen [10 ]
机构：
[1] NYU Sch Med, NYU Perlmutter Canc Ctr, New York, NY USA
[2] Dana Farber Canc Inst, ECOG ACRIN Biostatist Ctr, Boston, MA USA
[3] Northwestern Univ Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL USA
[4] Emory Univ, Atlanta, GA USA
[5] Indiana Univ Sch Med, Indianapolis, IN USA
[6] Stanford Canc Inst, Stanford, CA USA
[7] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA
[8] Johns Hopkins Med Inst, Div Hematol Malignancies, SKCCC, Baltimore, MD USA
[9] Washington Univ, St Louis, MO USA
[10] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1182/blood.V128.22.1106.1106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106
引用
收藏
页数：6
相关论文
共 50 条
  • [1] A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).
    Diefenbach, Catherine S. Magid
    Li, Hailun
    Kahl, Brad S.
    Robertson, Michael J.
    Cohen, Jonathan
    Advani, Ranjana H.
    Ambinder, Richard
    Fenske, Timothy S.
    Ansell, Stephen Maxted
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)
    Diefenbach, C. S. M.
    Hong, F.
    Ambinder, R. F.
    Cohen, J. B.
    Robertson, M. J.
    Fenske, T. S.
    Advani, R.
    Kahl, B. S.
    Ansell, S.
    HAEMATOLOGICA, 2016, 101 : 44 - 45
  • [3] A Phase I Study With an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 18 - 19
  • [4] A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
    Diefenbach, Catherine
    Hong, Fangxin
    Ambinder, Richard F.
    Cohen, Jonathon B.
    Robertson, Michael
    David, Kevin A.
    Advani, Ranjana H.
    Fenske, Timothy S.
    Barta, Stefan Klaus
    Palmisano, Neil
    Svoboda, Jakub
    Morgan, David
    Karmali, Reem
    Kahl, Brad S.
    Ansell, Stephen M.
    BLOOD, 2018, 132
  • [5] Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)
    Diefenbach, Catherine S.
    Hong, Fangxin
    Cohen, Jonathon B.
    Robertson, Michael J.
    Ambinder, Richard F.
    Fenske, Timothy S.
    Advani, Ranjana H.
    Kahl, Brad S.
    Ansell, Stephen
    BLOOD, 2015, 126 (23)
  • [6] Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)
    Hong, Fangxin
    Thanarajasingam, Gita
    Ansell, Stephen M.
    Ambinder, Richard F.
    Cohen, Jonathon B.
    Robertson, Michael
    David, Kevin A.
    Advani, Ranjana H.
    Fenske, Timothy S.
    Barta, Stefan Klaus
    Palmisiano, Neil
    Svoboda, Jakub
    Morgan, David
    Karmali, Reem
    Witzig, Thomas E.
    Dueck, Amylou C.
    Novotny, Paul
    Kahl, Brad S.
    Diefenbach, Catherine
    BLOOD, 2018, 132
  • [7] Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)
    Diefenbach, Catherine S.
    Jegede, Opeyemi
    Ansell, Stephen M.
    Steidl, Christian
    Natkunam, Yasodha
    Scott, David W.
    Mehta-Shah, Neha
    Amengual, Jennifer E.
    Forlenza, Christopher J.
    Cole, Peter D.
    Bartlett, Nancy L.
    David, Kevin A.
    Advani, Ranjana H.
    Ambinder, Richard F.
    Thomas, Sachdev
    Ibrahimi, Sami
    Kahl, Brad S.
    BLOOD, 2023, 142
  • [8] Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)
    Diefenbach, Catherine S.
    Gonzalez-Kozlova, Edgar
    Del Valle, Diane Marie
    Huang, Hsin-Hui
    Jegede, Opeyemi
    Barcessat, Vanessa
    Tuballes, Kevin
    Kelly, Geoffrey
    Patel, Manishkumar
    Xie, Hui
    Harris, Jocelyn
    Argueta, Kimberly
    Nie, Kai
    Moravec, Radim
    Altreuter, Jennifer
    Duose, Dzifa Yawa
    Kahl, Brad S.
    Ansell, Stephen M.
    Yu, Joyce
    Cerami, Ethan
    Lindsay, James
    Wistuba, Ignacio
    Kim-Schulze, Seunghee
    Gnjatic, Sacha
    BLOOD, 2023, 142
  • [9] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2017, 130
  • [10] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
12345